Enterprise Value

6.249B

Cash

497.9M

Avg Qtr Burn

-31.05M

Short % of Float

4.08%

Insider Ownership

2.60%

Institutional Own.

98.59%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Caplyta (Lumateperone) Details
Schizophrenia, Mental health

Approved

Quarterly sales

Caplyta (Lumateperone) Details
Bipolar depression, Mental health

Approved

Quarterly sales

Caplyta (Lumateperone) Details
Major depressive disorder, Mental health

Big Mover™

Susp. Mover™

Phase 3

Data readout

Phase 2

Data readout

Lenrispodun (ITI-214) (PDE1 inhibitor) Details
Heart disease, Parkinson's disease

Phase 2

Data readout

Phase 1

Data readout

ITI-333 Details
Sleeping disorder, Bipolar depression, Opioid use disorder

Phase 1

Update

LAI (lumateperone long acting injection) Details
Mental health, Schizophrenia, Major depressive disorder, Bipolar disease

Phase 1

Initiation